The combi-targeting concept: In vitro and in vivo fragmentation of a stable combi-nitrosourea engineered to interact with the epidermal growth factor receptor while remaining DNA reactive

Clinical Cancer Research

Volumn 13, Issue 1, 2007, Pages 331-340

  Qiu, Qiyu ^a   Domarkas, Juozas ^a   Banerjee, Ranjita ^a   Merayo, Nuria ^a   Brahimi, Fouad ^a   McNamee, James P ^b   Gibbs, Bernard F ^a   Jean Claude, Bertrand J ^a  

^a ROYAL VICTORIA HOSPITAL   (Canada)

^b HEALTH CANADA   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

AMINE; ANTINEOPLASTIC AGENT; CARMUSTINE; DRUG METABOLITE; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR KINASE; JDA 35; JDA 41; JDA 58; NITROSOUREA DERIVATIVE; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CANCER CELL CULTURE; CELL FREE SYSTEM; CELL PROLIFERATION; COMET ASSAY; CONTROLLED STUDY; DNA DAMAGE; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG DNA INTERACTION; DRUG HYDROLYSIS; DRUG MECHANISM; DRUG RECEPTOR BINDING; DRUG TARGETING; FLUORESCENCE MICROSCOPY; FRAGMENTATION REACTION; GENE TARGETING; HUMAN; IC 50; IN VITRO STUDY; IN VIVO STUDY; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; STUDENT T TEST; TANDEM MASS SPECTROMETRY; TUMOR XENOGRAFT; WESTERN BLOTTING;

ANIMALS; CELL LINE, TUMOR; COMET ASSAY; DNA; DNA DAMAGE; DRUG SCREENING ASSAYS, ANTITUMOR; HUMANS; INHIBITORY CONCENTRATION 50; MALE; MASS SPECTROMETRY; MICE; MICROSCOPY, FLUORESCENCE; NEOPLASM TRANSPLANTATION; NITROSOUREA COMPOUNDS; PHOSPHORYLATION; RECEPTOR, EPIDERMAL GROWTH FACTOR;

EID: 33846302437     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-06-0812     Document Type: Article

References (41)

1. Ghosh S, Narla RK, Zheng Y, et al. Structure-based design of potent inhibitors of EGF-receptor tyrosine kinase as anti-cancer agents. Anticancer Drug Des 1999;14:403-10.
2. Ciardiello F, Caputo R, Bianco R, et al. Antitumor effect and potentiation of cytotoxic drugs activity in human cancer cells by ZD-1839 (Iressa), an epidermal growth factor receptor-sensitive tyrosine kinase inhibitor. Clin Cancer Res 2001;6:2053-63.
3. Fry DW. Inhibition of the epidermal growth factor receptor family of tyrosine kinase as an approach to cancer chemotherapy: progression from reversible to irreversible inhibitors. Pharmacol Ther 1999;82: 207-18.
4. Tsai CM, Levitzki A, Wu LH, et al. Enhancement of chemosensitivity by tyrphostin AG825 in high-p185(neu) expressing non-small cell lung cancer cells. Cancer Res 1996;56:1068-74.
5. Vergnene A, Thomas P, Robinet G, et al. High-dose ifosfamide for patients with stage IV non-small cell lung cancer: phase II trial from the Groupe francais de pneumo-cancerologie (GFPC) [in French]. Bull Cancer 2003;86:1017-21.
6. 6-(2-chloroethyl)guanine mediates the biological effects of chloroethylnitrosoureas. Environ Health Perspect 1985;62:119-26.
7. 6-alkylguanine-DNA alkyltransferase and N,N′-bis(2-chloroethyl)-N-nitrosourea. Biochem Pharmacol 1995;50:1141-8.
8. Qiu Q, Dudouit F, Matheson SL, et al. The combi-targeting concept: a novel 3,3-disubstituted nitrosourea with EGFR tyrosine kinase inhibitory properties. Cancer Chemother Pharmacol 2003;51:1-10.
9. Qiu Q, Dudouit F, Banerjee R, McNamee JP, Jean-Claude BJ. Inhibition of cell signaling by the combi-nitrosourea FD137 in the androgen independent DU145 prostate cancer cell line. Prostate 2004;59: 13-21.
10. Domarkas J, Dudouit F, Williams C, et al. The combi-targeting concept: synthesis of stable nitrosoureas designed to inhibit the epidermal growth factor receptor (EGFR). J Med Chem 2006;49:3544-52.
11. Matheson SL, McNamee J, Jean-Claude BJ. Differential responses of EGFR/AGT-expressing cells to the "combi-triazene" SMA41. Cancer Chemother Pharmacol 2003;51:11-20.
12. Banerjee R, Rachid Z, McNamee JP, Jean-Claude BJ. Synthesis of a prodrug designed to release multiple inhibitors of the epidermal growth factor receptor (EGFR) tyrosine kinase and an alkylating agent: a novel tumour targeting concept. J Med Chem 2003;46: 5546-51.
13. Schmidt-Ullrich RK, Contessa JN, Lammering G, Amorino G, Lin P-S. ERBB receptor tyrosine kinases and cellular radiation responses. Oncogene 2003;22: 5855-65.
14. Suo Z, Risberg B, Kalsson MG, et al. EGFR family expression in breast carcinomas. c-erbB-2 and c-erbB-4 receptors have different effects on survival. J Pathol 2002;196:17-25.
15. Moyer JD, Barbacci EG, Iwata K, et al. Induction of apoptosis and cell cycle arrest by CP-358, 774, an inhibitor of epidermal growth factor receptor tyrosine kinase. Cancer Res 1997;57:4838-48.
16. Vincent PW, Bridges AJ, Dykes DJ, et al. Anticancer efficacy of the irreversible EGFR tyrosine kinase inhibitor PD 0169414 against human tumor xenografts. Cancer Chemother Pharmacol 2000;45:231-8.
17. Smaill JB, Palmer BD, Rewcastle Gw, et al. Tyrosine kinase inhibitors. 15. 4-(phenylamino)quinazoline and 4-(phenylamino)pyrido[d]pyrimidine acrylamides as irreversible inhibitors of the ATP binding site of the epidermal growth factor receptor. J Med Chem 1999; 42:1803-15.
18. Skehan P, Storeng R, Scudiero D, et al. New colorimetric cytotoxicity assay for anti-cancer drug screening. J Natl Cancer Inst 1990;82:1107-12.
19. Fricker SP, Buckley RG. Comparison of two colorimetric assays as cytotoxicity endpoints for an in vitro screen for antitumour agents. Anticancer Res 1996;16: 3755-60.
20. Rubinstein LV, Shoemaker RH, Paull KD, et al. Comparison of in vitro anticancer-drug-screening data generated with a tetrazolium assay versus a protein assay against a diverse panel of human tumor cell lines. J Natl Cancer Inst 1990;82:1113-8.
21. Tari A, Lopez-Berestein G. Serum predominantly activates MAPK and AKT kinases in EGFR- and ErbB2-overexpressing cells, respectively. Int J Cancer 2000;86:295-7.
22. Brahimi F, Matheson SL, Dudouit F, McNamee JP, Tari AM, Jean-Claude BJ. Inhibition of epidermal growth factor receptor-mediated signaling by "combi-triazene" BJ2000, a new probe for combi-targeting postulates. J Pharmacol Exp Ther 2002; 303:238-46.
23. Matheson SL, Brahimi F, Jean-Claude BJ. The combi-targeting concept: intracellular fragmentation of the binary epidermal growth factor (EGFR)/DNA targeting "combi-triazene" SMA41. Biochem Pharmacol 2004;67:1131-8.
24. Brahimi F, Rachid Z, McNamee JP, Li Y, Tari AM, Jean-Claude BJ. Multiple mechanisms of action of ZR2002 in human breast cancer cells: a novel combi-molecule designed to block signaling mediated by the erbB family of oncogenes and to damage genomic DNA. Int J Cancer 2004;112:484-91.
25. McNamee JP, McLean JRN, Ferrarotto CL, Bellier PV. Comet assay: rapid processing of multiple samples. Mutat Res 2000;466:63-9.
26. Sirotnak FM, She Y, Lee F, Chen J, Scher HI. Studies with CWR22 xenografts in nude mice suggest that ZD1839 may have a role in the treatment of both androgen-dependent and androgen-independent human prostate cancer. Clin Cancer Res 2002; 8:3870-6.
27. Morris MJ, Scher HI. Novel strategies and therapeutics for the treatment of prostate carcinoma. Cancer 2000;89:1329-48.
28. Grasso AW, Wen D, Miller CM, Rhim JS, Pretlow TG, Kung HJ. ErbB kinases and NDF signaling in human prostate cancer. Oncogene 1997;15:2705-16.
29. 6-alkylguanine-DNA alkyl-transferase. Prog Nucleic Acid Res Mol Biol 1995;51: 167-223.
30. Smith MT, Evans CG, Doane-Setzer P, Mannervik B. Denitrosation of 1,3-bis(2-chloroethyl)-1-nitrosourea by class μ glutathione transferases and its role in cellular resistance in rat brain tumor cells. Cancer Res 1989; 49:2621-5.
31. Aukerman SL, Brundrett RB, Hilton J, Hartman PE. Effect of plasma and carboxylesterase on the stability, mutagenicity, and DNA cross-linking activity of some direct acting N-nitroso compounds. Cancer Res 1983; 43:175-81.
32. Thust R, Mendel J, Bach B, Schwarz H. Detection of a deuterium isotope effect in di- and trisubstituted alkylphenylnitrosoureas. An SCE study in Chinese hamster V79-E cells. Carcinogenesis 1985; 6:873-6.
33. Thust R, Schneider M. Serine hydrolases activate/ inactivate trisubstituted nitrosoureas in dependence on intra- and extracellular enzyme location: an SCE study in Chinese hamster V79-E cells. Carcinogenesis 1989;10:1787-91.
34. Matheson SL, McNamee JP, WangT, Alaoui-Jamali MA, Tari A, Jean-Claude BJ. The combi-targeting concept: dissection of the binary mechanism of action of the combi-triazene SMA41 in vitro and antiproliferative effects in vivo. J Pharmacol Exp Ther 2004;311: 1163-70.
35. Colvin M, Brundett R. Chemical decomposition of chloroethylnitrosoureas. In: Nitrosoureas, current status and development. London, New York: Academic Press; 1980. 43-9.
36. Weber GF, Waxman DJ. Denitrosation of the anticancer drug 1,3-bis(2-chloroethyl)-1-nitrosourea catalyzed by microsomal glutathione S-transferase and cytochrome P450 monooxygenases. Arch Biochem Biophys 1993;307:369-78.
37. El Sheikh SS, Domin J, Abel P, Stamp G, Lalani el-N. Phosphorylation of both EGFR and ErbB2 is a reliable predictor of prostate cancer cell proliferation in response to EGF. Neoplasia 2004;6:846-53.
38. Yacoub A, McKinstry R, Hinman D, Chung T, Dent P, Hagan MP. Epidermal growth factor and ionizing radiation up-regulate the DNA repair genes XRCC1 and ERCC1 in DU145 and LNCaP prostate carcinoma through MAPK signaling. Radiat Res 2003;159: 439-52.
39. Hagan M, Yacoub A, Dent P. Ionizing radiation causes a dose-dependent release of transforming growth factor α in vitro from irradiated xenografts and during palliative treatment of hormone-refractory prostate carcinoma. Clin Cancer Res 2004;10: 5724-31.
40. Yang A, Bagheri-yarmand, Wang R-A, Asam L, Papdimitrakopoulou V, Kumar R. The epidermal growth factor receptor tyrosine kinase inhibitor ZD1839 (Iressa) suppresses s-Src and Park1 pathways and invasiveness of human cancer cells. Clin Cancer Res 2004;10:658-67.
41. Murthy U, Basu M, Sen-Majumdar A, Das M. Perinuclear location and recycling of epidermal growth factor receptor kinase: immunofluorescent visualization using antibodies directed to kinase and extracellular domains. J Cell Biol 1986;103:333-42.